Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 20:32:41时区推断·⟳ 抓取 20:33:17·⚡ 决策 08-04 22:26:47 +1h53m·83.9 天前
Evolus扩大Estyme透明质酸凝胶在加拿大、澳大利亚和新西兰的独家商业化权利
新增三地市场TAM约5亿美元，其中约40%为皮肤填充剂，但商业化预计到2028年且需监管批准。
📄 原文Investing.com↗ 原文
Evolus expands hyaluronic acid gel rights to three markets
BofA says this memory stock could double. Here are 5 reasons why NEWPORT BEACH, Calif. - Evolus Inc. (NASDAQ:EOLS) anno…
不做 Evolus（EOLS.US）
同一Evolus/Symatese授权扩展已处理为不做；商业化到2028年且需审批，当前无新增短线可交易增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 high ↗
消息传播链
- 2026-08-04 12:46 UTC官方确认/否认ir_page/search_processed_events声称一手 · 未核验已处理库显示Evolus扩大与Symatese合作、获得Estyme三地独家商业化权利的同一催化已决策为不做。
- 转述协议扩展至加拿大、澳大利亚、新西兰，商业化预计2028年并需监管批准。
关键理由
- 新增三地市场TAM约5亿美元，其中约40%为皮肤填充剂，但商业化预计到2028年且需监管批准。
- 公司需支付首付款、里程碑款、转让价和中个位数销售royalty，短线利润增量尚不能量化。
主要风险
- 已处理库在08-04 12:46 UTC命中同一Evolus/Symatese催化并结论不做，当前为重复转述。
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 2,185 字
BofA says this memory stock could double. Here are 5 reasons why
NEWPORT BEACH, Calif. - Evolus Inc. (NASDAQ:EOLS) announced Tuesday it has amended its licensing and distribution agreement with Symatese to obtain exclusive rights to commercialize the Estyme collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand.
The agreement extends Evolus’ existing partnership with Symatese and adds three markets to its hyaluronic acid gel portfolio. The company currently markets Estyme in the United States under the brand name Evolysse. Commercialization in the three new territories is expected in 2028, subject to regulatory approvals.
The neurotoxin and dermal filler markets across Canada, Australia, and New Zealand represent a total addressable market of approximately $500 million annually, with about 60% attributable to neurotoxins and 40% to dermal fillers, according to the press release statement.
"This alignment of our portfolio ensures we can deliver a consistent Evolus experience, strengthens our competitive position, and allows us to maximize the long-term value of the commercial platform we have built," said David Moatazedi, President and Chief Executive Officer of Evolus.
Under the agreement terms, Symatese will handle product development, manufacturing, clinical support, and regulatory activities for obtaining marketing approvals in the licensed territories. Evolus will make an upfront payment to Symatese plus additional payments tied to regulatory approval milestones. The company will purchase product at an agreed transfer price and pay a mid-single digit royalty based on net sales.
The Estyme collection features injectable hyaluronic acid gels using Symatese’s Cold-X technology. The agreement allows Evolus to offer both its Nuceiva neurotoxin and Estyme hyaluronic acid gels in all international markets where it currently operates.
The company stated the agreement is expected to be accretive to its international gross margins while leveraging its existing commercial organization and distribution infrastructure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEWPORT BEACH, Calif. - Evolus Inc. (NASDAQ:EOLS) announced Tuesday it has amended its licensing and distribution agreement with Symatese to obtain exclusive rights to commercialize the Estyme collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand.
The agreement extends Evolus’ existing partnership with Symatese and adds three markets to its hyaluronic acid gel portfolio. The company currently markets Estyme in the United States under the brand name Evolysse. Commercialization in the three new territories is expected in 2028, subject to regulatory approvals.
The neurotoxin and dermal filler markets across Canada, Australia, and New Zealand represent a total addressable market of approximately $500 million annually, with about 60% attributable to neurotoxins and 40% to dermal fillers, according to the press release statement.
"This alignment of our portfolio ensures we can deliver a consistent Evolus experience, strengthens our competitive position, and allows us to maximize the long-term value of the commercial platform we have built," said David Moatazedi, President and Chief Executive Officer of Evolus.
Under the agreement terms, Symatese will handle product development, manufacturing, clinical support, and regulatory activities for obtaining marketing approvals in the licensed territories. Evolus will make an upfront payment to Symatese plus additional payments tied to regulatory approval milestones. The company will purchase product at an agreed transfer price and pay a mid-single digit royalty based on net sales.
The Estyme collection features injectable hyaluronic acid gels using Symatese’s Cold-X technology. The agreement allows Evolus to offer both its Nuceiva neurotoxin and Estyme hyaluronic acid gels in all international markets where it currently operates.
The company stated the agreement is expected to be accretive to its international gross margins while leveraging its existing commercial organization and distribution infrastructure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。